TET2 and chronic myelomonocytic leukemia: Further, heterozygous loss of Tet2 initiates aberrant hematopoiesis in vivo [61] and the homozygous loss leads to a wide spectrum of myeloid malignancies including MDS, CMML, and sarcoma (Table 1) [59,60].